Medtronic has positive long-term extravascular ICD study results - MassDevice
Medtronic shared long-term results from its global EV-ICD pivotal trial at the 2024 ESC Congress, showing sustained safety and effectiveness of the Aurora EV-ICD system, which delivers defibrillation and pacing therapies without transvenous risks. The trial, involving 356 patients across 46 sites, reported high success rates for ATP and shock therapies, low complication rates, and improved patient quality of life.
Highlighted Terms
Related News
Medtronic shared long-term results from its global EV-ICD pivotal trial at the 2024 ESC Congress, showing sustained safety and effectiveness of the Aurora EV-ICD system, which delivers defibrillation and pacing therapies without transvenous risks. The trial, involving 356 patients across 46 sites, reported high success rates for ATP and shock therapies, low complication rates, and improved patient quality of life.